Published in Cancer Weekly, August 3rd, 2004
According to recent research from the United States, "BCR-ABL and v-ABL are oncogenic forms of the Abl tyrosine kinase that can cause leukemias in mice and humans. ABL oncogenes trigger multiple signaling pathways whose contribution to transformation varies among cell types."
"Activation of phosphoinositide 3-kinase (P13K) is essential for ABL-dependent proliferation and survival in some cell types, and global P13K inhibitors can enhance the antileukemia effects of the Abl kinase inhibitor imatinib.
"Although a significant fraction of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.